Trial
NCT04190056
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of California, San Francisco
Collaborators
Merck Sharp & Dohme LLC
Condition
Anatomic Stage IV Breast Cancer AJCC v8
Intervention
Pembrolizumab
Why stopped
Change in practice patterns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-31